Psychedelics for Clinicians 101 & 102


Elizabeth Nielson

New York University & Fluence

Ingmar Gorman

MAPS & Fluence

2-Day Workshop for Clinicians

New dates! 21-22 September 2020

Haarlem, The Netherlands


This 2-day training is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. This interactive training includes role plays, demonstrations, case examples, and experiential learning opportunities. This training is co-organized by Fluence.

Psychedelics 101

Your patients are curious and so are you: What is all this about psychedelics being used for treatment of addiction and trauma? This session gives an overview of psychedelic drugs, their history, and current research with MDMA and Psilocybin-assisted therapy. This program includes an overview of recent and current clinical trials, outcomes, legal status, and what it all means for the future of addiction and trauma treatment.

Psychedelics 102

This day introduces clinical skills for psychedelic harm reduction and integration work in the clinical setting. This program focuses on translating research findings into clinical practice including working with patients who are considering using psychedelics, actually using psychedelics, or have used them. Includes discussion of assessment and integration techniques, resources, and legal and ethical issues.


Dr. Elizabeth Nielson is a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression.

Dr. Ingmar Gorman is a psychologist who specializes in assisting populations who have a relationship with psychedelics. He is the site co-principal investigator and therapist on a Phase 3 clinical trial studying MDMA-assisted psychotherapy for post-traumatic stress disorder. After completing his NIH postdoctoral fellowship at New York University, Dr. Gorman stepped down as director of the Psychedelic Education and Continuing Care Program to focus his efforts on Fluence and the training of future therapists.


All previous registrations (for April) will automatically be converted to the new workshop dates:

Monday 21 & Tuesday 22 September, 2020. 09:00 – 18:00


Onder de Toren, A. Hofmanweg 1, Haarlem, The Netherlands


Regular: €300


A limited number of tickets is now available for this exclusive 2-day workshop


€ 300